Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Durvalumab + Tremelimumab||Phase II||Actionable||In a Phase II trial, the combination treatment of Imfinzi (durvalumab) and Tremelimumab resulted in a greater overall survival, 6.6 months versus 4.1 months (P=0.07), compared to best supportive care in patients with advanced colorectal cancer (PMID: 32379280; NCT02870920).||32379280|